Articles by William Looney - Pharmaceutical Executive


Articles by William Looney

Industry Forecast 2013

Jan 25, 2013

As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.

The Permanent Campaign

Jan 1, 2013

Promoting the merits of private-sector drug innovation is no easy task—just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.

The Long Swim—Upstream

Jan 1, 2013

2013 may be a number associated with the fate of the luckless, but our annual review of the business and policy environment for Big Pharma suggests otherwise—as we near the midway point in the "tween" decade, there is good fortune in store for those with the perspective that comes with the long view.

2012: Year of Record

Dec 1, 2012

The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry—for good or bad—in 2012.

The Puzzle Master: EMA's Guido Rasi

Dec 1, 2012

Europe's chief regulator charts a strategy from many moving parts. Dr Guido Rasi talks to Pharm Exec's William Looney.

Simple Questions for Spain

Nov 1, 2012

Spain's leading business school, IESE, organized an expert conference on October 2-3 to address two simple questions. First, how can providers and payers work together to generate more value from existing resources? Second, what must be done to ensure the system continues to create value in the first place?

Lundbeck: Bidding for the Stars and Stripes

Oct 1, 2012

Pharm Exec takes a look at how a mid tier player — Denmark's Lundbeck — is counting on the momentum of the big US market to vault it to global leadership position.

Three Ways to the Future

Oct 1, 2012

Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. Solving the puzzle correctly—with a new product as the sum of its parts—depends on making that lengthy progression from basic science to registration as linear as possible.

The Margin Call

Sep 1, 2012

Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.


Click here